ADC Case Study: Overcoming Metastatic Breast Cancer

ADC Case Study: Overcoming Metastatic Breast Cancer

Expert Commentary Professor Yuan Zhongyu Department of Internal Medicine, Sun Yat-sen University Cancer Prevention and Treatment Center Chief Physician, MD, Doctoral Supervisor Engaged in clinical and research work on breast cancer for many years, has presided over and participated in over 20 clinical studies, involved in several research projects such as the National 863 Program … Read more

Case Sharing of ADC: A HER2-Positive Breast Cancer Case

Case Sharing of ADC: A HER2-Positive Breast Cancer Case

Expert Commentary Professor Feng Jifeng Chief Physician, Professor, Doctoral Supervisor Secretary of the Party Committee, Jiangsu Provincial Cancer Hospital/Nanjing Medical University Affiliated Cancer Hospital Member of the Expert Committee on Rational Drug Use, National Health Commission Council Member of the Chinese Medical Association, Member of the Internal Medicine Group of the Oncology Branch Vice President … Read more

ADC Drug Combination: How to Achieve 1+1>2

ADC Drug Combination: How to Achieve 1+1>2

Antibody-drug conjugates (ADC) are a novel type of medication that couples monoclonal antibodies, which specifically recognize cancer cell surface antigens, with cytotoxic chemotherapy drugs through specific linkers, exerting a significant tumor-killing effect. Currently, 15 ADC drugs, represented by trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd, DS-8201), have been approved globally, significantly changing the treatment landscape … Read more

Overview of ADC Drugs for Breast Cancer

Overview of ADC Drugs for Breast Cancer

As early as 1913, during the 17th International Medical Congress, Professor Paul Ehrlich proposed the concept of the “magic bullet”, using monoclonal antibodies to specifically deliver cytotoxic drugs to tumor cells, thereby achieving the goal of killing tumor cells. With the development of monoclonal antibody production technology and the exploration of antibody conjugates, antibody-drug conjugates … Read more

Illustrated Breast ‘Donation’ | Issue 066: CA 15-3 Specific Molecularly Imprinted Polymer Nanoparticle-Based Voltammetric Sensor for Breast Cancer Monitoring

Illustrated Breast 'Donation' | Issue 066: CA 15-3 Specific Molecularly Imprinted Polymer Nanoparticle-Based Voltammetric Sensor for Breast Cancer Monitoring

This issue’s illustrations are from the article “CA 15-3-specific molecularly imprinted polymer nanoparticles-based voltammetric sensor for breast cancer monitoring” published on February 16, 2025, in Talanta (IF 5.6). 1. CA 15-3 specific nano molecularly imprinted polymers (nanoMIPs) have been developed and used as recognition sites for CA 15-3 detection; 2. The combination of nanoMIPs with … Read more

Professor Wang Shu: Long-term Follow-up and Meta-analysis of Adjuvant Endocrine Therapy for Premenopausal HR+ Early Breast Cancer Patients with OFS+AI

Professor Wang Shu: Long-term Follow-up and Meta-analysis of Adjuvant Endocrine Therapy for Premenopausal HR+ Early Breast Cancer Patients with OFS+AI

Click the blue text to follow us! From December 7 to 10, 2021, the 44th San Antonio Breast Cancer Symposium (SABCS) was grandly held. At this conference, updated follow-up data from the TEXT and SOFT studies over 13 years [1] were presented, along with the results of four randomized controlled trials (ABCSG 12, TEXT, SOFT, … Read more

HER2 Low-Positive Breast Cancer: A Potential New Subtype for Precision Treatment

HER2 Low-Positive Breast Cancer: A Potential New Subtype for Precision Treatment

Author: Cornflower This article is published with the author’s permission by Yiliao Tong. Please do not reproduce without authorization. Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a highly aggressive molecular subtype with poor prognosis. The advent of anti-HER2 targeted therapies has significantly improved its prognosis. Currently, international standards generally consider that … Read more

Exciting News: DS-8201 Brings New Hope for HER2 Positive Breast Cancer Patients!

Exciting News: DS-8201 Brings New Hope for HER2 Positive Breast Cancer Patients!

With the advancement of breast cancer treatment, there are increasingly more life-saving drugs available for patients. The emergence of new treatment methods is like a relay race, passing on the hope of life, even in the face of recurrence and metastasis, it is no longer a dead end. In the past, anti-HER2 treatments saved countless … Read more

Case Report: HER2 Negative to Positive Conversion in Breast Cancer Re-biopsy?! Benefits of DS-8201 Treatment

Case Report: HER2 Negative to Positive Conversion in Breast Cancer Re-biopsy?! Benefits of DS-8201 Treatment

Open the public account and set it as a “star”. Follow us to learn more about cancer information!~ Breast Cancer In recent years, the treatment of breast cancer has been influenced by the practice of precision oncology, requiring personalized medical care based on specific tumor characteristics. The treatment of breast cancer primarily depends on the … Read more